Abbonarsi

Patients with heart failure who die in hospice - 21/08/11

Doi : 10.1016/j.ahj.2004.06.019 
Cheryl Hoyt Zambroski, PhD, RN a, , Debra K. Moser, DNSc, RN, FAAN b, Lynn P. Roser, MSN, RN b, Seongkum Heo, PhD, RN b, Misook L. Chung, PhD, RN b
a School of Nursing, University of Louisville, Louisville, Ky 
b College of Nursing, University of Kentucky, Lexington, Ky 

 Reprint requests: Cheryl Hoyt Zambroski, PhD, RN, School of Nursing, University of Louisville, 555 S. Floyd Street, Louisville, KY 40292.

This study was supported by the University of Louisville School of Nursing Summer Research Grant and the University of Kentucky College of Nursing Gill Trust Fund.

Riassunto

Background

Patients with end-stage heart failure experience disability, dyspnea, pain, and suffering at the end of life despite progress in treatment approaches. Little is known about the patients with heart failure in hospice and the impact of hospice care on health-related outcomes.

Methods and Results

The purposes of this retrospective, descriptive chart review were to (1) describe the characteristics of patients who receive hospice care, (2) identify symptoms most commonly reported by patients with heart failure in hospice during the last 7 days of life, and (3) identify interventions used by hospice nurses to manage the symptoms. The majority of the patients were women, widowed, and white. Median length of stay was 10 days. Nearly 37% of the patients were admitted to hospice during the last week of life. Primary symptoms at admission for hospice care included dyspnea, confusion at least some of the time, and poor appetite. There was no statistically significant difference in symptoms between the day of admission for hospice care and the day of death. Symptom management strategies included oxygen, family reassurance or education, skin care, and patient education. Medications commonly used to relieve symptoms included antianxiety medications, morphine, and/or other narcotics. Although mainstay heart failure drugs had been prescribed for some patients, prescription rates were low and not in line with current guideline recommendations, nor were those medications recorded as being used for symptom management.

Conclusion

Further research including prospective study is needed to clearly articulate the impact of hospice care on patients and families affected by heart failure.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


© 2005  Elsevier Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 149 - N° 3

P. 558-564 - Marzo 2005 Ritorno al numero
Articolo precedente Articolo precedente
  • Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT)
  • Aldo P. Maggioni, Roberto Latini, Peter E. Carson, Steven N. Singh, Simona Barlera, Robert Glazer, Serge Masson, Elisabetta Cerè, Gianni Tognoni, Jay N. Cohn, for the Val-HeFT Investigators
| Articolo seguente Articolo seguente
  • Very early cardiac magnetic resonance imaging for quantification of myocardial tissue perfusion in patients receiving tirofiban before percutaneous coronary intervention for ST-elevation myocardial infarction
  • Henning Steen, Stephanie Lehrke, Uwe K.H. Wiegand, Constanze Merten, Lydia Schuster, Gert Richardt, Christian Kulke, Hans B. Gehl, Joao A. Lima, Hugo A. Katus, Evangelos Giannitsis

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.